CB 813d

Showing 1 posts of 1 posts found.

Targcept image

Targacept and Catalyst sign $100 million deal

March 9, 2015
Research and Development, Sales and Marketing CB 813d, PF-05280602, Targecept, blood disorder, catalyst biosciences

Targacept and Catalyst Biosciences have signed a merger agreement which will see them develop new treatment options for patients with …

The Gateway to Local Adoption Series

Latest content